The treatment is designed to slow the rate of degeneration of retinal cells, slowing the progression of geographic atrophy.
New York City-based ophthalmologist, Dr. Jason Slakter has begun administering Syfovre® following its approval as a groundbreaking treatment for geographic atrophy in patients with dry age-related macular degeneration (AMD).
Currently, there is no cure for dry AMD, and, until the approval of Syfovre, no treatment to address the symptoms of the disease. Syfovre, however, offers a new approach to treating geographic atrophy in dry AMD patients. The treatment is designed to slow the rate of degeneration of retinal cells, slowing the progression of geographic atrophy, and providing patients with visual function for many more months or years.
Dr. Slakter, who has been at the forefront of AMD research, is excited to be among the first doctors to offer Syfovre to his patients. He says that the treatment has the potential to be a game-changer in the field of ophthalmology, and that he is eager to be able to offer this treatment to his patients.
"I've spent my career working to find new and better ways to treat AMD, and I believe that Syfovre has the potential to be a major breakthrough," Dr. Slakter said. "I'm honored to be among the first doctors to administer this treatment, and I'm eager to see the positive impact it will have on my patients' lives."